Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_1267_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Foreword
- •Foreword
- •Contents
- •References
- •2.1 Introduction
- •2.2.1 Crohn’s Disease
- •2.2.2 Ulcerative Colitis
- •References
- •3.2.1 Bacterial Sensing
- •3.2.1.2 Toll-Like Receptors, TLRs
- •3.2.2 Autophagy: Autophagy-Related 16-like 1, ATG16L1
- •3.1 Introduction
- •3.2.4.1 Interleukin-23 Receptor, IL-23R
- •3.2.4.2 Fractalkine Receptor 1, CX3CR1
- •3.2.4.3 Transforming Growth Factor Beta (TGF-β)
- •3.2.4.4 Angiotensinogen
- •3.2.4.5 Tumour Necrosis Factor Alpha (TNFα)
- •3.2.6 Cell Signalling: Janus Kinase 2 (JAK2)
- •3.2.8 Other Processes
- •References
- •4.1 Introduction
- •4.2 Genetics
- •4.3 Epigenetics
- •4.5 DNA Methylation
- •4.9 MicroRNA
- •4.12 Summary
- •References
- •5.1 Introduction
- •5.2.1 TNFα
- •5.2.2 Th1 Cytokines
- •5.2.3 IL-1 Cytokines
- •5.2.4 Th2 Cytokines
- •5.2.5 Th17 Cytokines
- •5.2.6 TL1A
- •5.3 “Regulatory” Cytokines
- •5.3.1 TGFβ
- •5.3.2 IL-10
- •5.4 Concluding Remarks
- •References
- •6.1.1.1 Collagens
- •6.1.1.3 Glycoproteins
- •6.2.1 Integrins
- •6.3.1 Extracellular Matrix Stiffness
- •6.3.1.1 Modeling Extracellular Matrix Stiffness
- •References
- •7.1 Introduction
- •7.5 Future Outlook
- •References
- •8.1 Introduction
- •8.2.1 Smoking
- •8.3 Conclusion
- •References
- •9.4 Conclusions
- •References
- •10.1 Ulcerative Colitis
- •10.1.1 Epidemiology
- •10.1.2 Etiology
- •10.2.1 Pathogenesis
- •References
- •11.4 Conclusion
- •References
- •12.1 Introduction
- •12.2 Clinical Biomarkers
- •12.3 Cellular Biomarkers
- •12.4 Serologic Biomarkers
- •12.5 Other Factors
- •12.6 Conclusions
- •References
- •13.1 Introduction
- •13.3 Bowel Ultrasound
- •13.4 Computed Tomography Enterography
- •13.5 Magnetic Resonance Imaging
- •13.5.2 Functional MR Imaging Techniques
- •13.5.3 Hybrid Imaging Techniques
- •13.6 Conclusion
- •References
- •14.1.1 Ultrasound Stiffness Imaging
- •14.1.2 Shear Wave Elastography
- •14.5 Conclusion
- •References
- •15.1 Introduction
- •15.2.1 Stricturing IBD
- •15.2.2 Stricturing CD
- •15.2.3 Stricturing UC
- •15.4.1 Steroids
- •15.4.2 5-ASA
- •15.4.3 Purine Analogs
- •15.4.4 Methotrexate
- •15.4.5 Anti-TNFs
- •15.4.6 Other Biologics
- •15.5 Other Measures
- •15.6 Conclusion
- •References
- •16.1 Introduction
- •17.2.4 Abscess
- •17.3 Stricturoplasty or Resection
- •17.4 Approach
- •16.6 Conclusion
- •References
- •17.1 Introduction
- •17.2.2 Fibrotic Phenotype
- •17.2.3 Fistulising Disease
- •17.4.1 Open
- •17.4.2 Handassisted
- •17.4.3 Multi-Port
- •17.4.4 Single-Port
- •17.4.5 Single Port versus Multi-Port
- •17.4.6 Decision Making
- •17.5 Anastomosis
- •17.7 Conclusion
- •References
- •18.1 Introduction
- •18.4.1 Initial Evaluation
- •18.5.1 Pre-IPAA (Afferent Limb/Ileostomy Closure Site)
- •18.5.2 The Fibrotic IPAA Body
- •18.5.3 Post-IPAA (Efferent Limb, Anal Canal)
- •18.6 Conclusion
- •References
- •19.2 Pathophysiology
- •19.3 Diagnosis
- •19.4 Surgical Approach
- •19.4.1 Resections
- •19.4.2 Strictureplasties
- •19.4.2.1 History
- •19.4.2.2 Indications
- •19.4.2.3 General Technique
- •19.4.2.4 Conventional Strictureplasties
- •Judd Strictureplasty
- •Moskel-Walske-Neumayer Strictureplasty
- •Jaboulay Strictureplasty
- •Poggioli Strictureplasty
- •19.4.2.6 Results
- •Short-Term Results
- •Long-Term Results
- •19.5 Future Perspectives
- •References
- •20.1 Introduction
- •20.6 Summary
- •References
- •21.1 Introduction
- •21.2 Wound Healing
- •21.3 Crohn’s Disease Fistula
- •21.7 Summary
- •References
- •22.1 Introduction
- •22.3 The Transforming Growth Factor-β (TGF-β) Pathways
- •22.4.1 Connective Tissue Growth Factor (CTGF/CCN2)
- •22.4.2 Platelet Derived Growth Factor
- •22.4.3 Wnt-Signaling
- •22.4.4 Hedgehog Signaling
- •22.4.5 Notch Signaling
- •22.6.1 Coagulation Stage
- •22.6.3 Fibrous Adhesion Stage
- •22.7.4 Material Barriers
- •22.7.5 Pharmaceutical Approaches
- •22.8.4 Smooth Muscle Cells
- •22.12 Conclusions
- •References
- •23.1 Introduction
- •23.2 Liver
- •23.2.1 Farnesoid X Receptor (FXR)
- •23.2.2 Lysyl Oxidase (LOXL2)
- •23.2.3 Statins
- •23.2.4 5-Hydroxytryptamine (5HT)
- •23.2.5 Caspase Inhibition
- •23.2.6 Chemokine Receptors CCR2/5
- •23.2.7 GR-MD-02
- •23.2.8 PPAR Gamma
- •23.3 Lung
- •23.3.1 Pirfenidone
- •23.3.2 Nintedanib/Tyrosine Kinase Inhibitors
- •23.3.3 Lysophospholipids
- •23.3.4 mTOR
- •23.3.5 Prostacyclin
- •23.3.6 Integrin αvβ6
- •23.3.7 Endothelin Receptor Antagonism
- •23.3.8 Interleukin (IL)-13
- •23.3.9 Connective Tissue Growth Factor
- •23.3.10 Serum Amyloid P
- •23.4 Kidney
- •23.4.2 Pyridoxamine
- •23.4.3 Janus Kinase (JAK)1/2
- •23.4.4 Bindarit-CCL (MCP) Inhibitor
- •23.4.5 Phosphodiesterase Inhibition
- •23.5 Skin
- •23.5.1 TGFβ Targeted Therapies
- •23.5.2 Thalidomide/Pomalidomide
- •23.5.3 Paquinimod
- •23.6 Heart
- •23.6.1 Renin Angiotensin Aldosterone System (RAAS)
- •23.6.2 Transforming Growth Factor (TGF)-β
- •23.7 Conclusion
- •References
- •Index

124
37. Hooper LV, Littman DR, Macpherson AJ.Interactions between the microbiota and the immune
system. Science. 2012;336(6086):1268–73.
38. Takeuchi O, Akira S.Pattern recognition receptors and inammation. Cell. 2010;140(6):805–20.
39. Burke JP, Cunningham MF, Watson RW, Docherty NG, Coffey JC, O’Connell PR.Bacterial
lipopolysaccharide promotes probrotic activation of intestinal broblasts. Br J Surg.
2010;97(7):1126–34.
40. Burke JP, Watson RW, Mulsow JJ, Docherty NG, Coffey JC, O’Connell PR.Endoglin nega-
tively regulates transforming growth factor beta1-induced probrotic responses in intestinal
broblasts. Br J Surg. 2010;97(6):892–901.
41. Miyazaki H, Kobayashi R, Ishikawa H, Awano N, Yamagoe S, Miyazaki Y, Matsumoto
T.Activation of COL1A2 promoter in human broblasts by Escherichia coli. FEMS Immunol
Med Microbiol. 2012;65(3):481–7.
42. Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, Wei D, Goldfarb KC,
Santee CA, Lynch SV, Tanoue T, Imaoka A, Itoh K, Takeda K, Umesaki Y, Honda K,
Littman DR. Induction of intestinal Th17 cells by segmented lamentous bacteria. Cell.
2009;139(3):485–98.
43. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly YM, Glickman JN,
Garrett WS. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell
homeostasis. Science. 2013;341(6145):569–73.
44. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ.Review article: the
role of butyrate on colonic function. Aliment Pharmacol Ther. 2008;27(2):104–19.
45. Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, Liu H, Cross JR, Pfeffer
K, Coffer PJ, Rudensky AY.Metabolites produced by commensal bacteria promote peripheral
regulatory T-cell generation. Nature. 2013;504(7480):451–5.
46. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, Nakanishi Y, Uetake C,
Kato K, Kato T, Takahashi M, Fukuda NN, Murakami S, Miyauchi E, Hino S, Atarashi K,
Onawa S, Fujimura Y, Lockett T, Clarke JM, Topping DL, Tomita M, Hori S, Ohara O, Morita
T, Koseki H, Kikuchi J, Honda K, Hase K, Ohno H. Commensal microbe-derived butyrate
induces the differentiation of colonic regulatory T cells. Nature. 2013;504(7480):446–50.
47. Pacheco RG, Esposito CC, Muller LC, Castelo-Branco MT, Quintella LP, Chagas VL, de Souza
HS, Schanaider A.Use of butyrate or glutamine in enema solution reduces inammation and
brosis in experimental diversion colitis. World J Gastroenterol. 2012;18(32):4278–87.
48. Maslowski KM, Mackay CR. Diet, gut microbiota and immune responses. Nat Immunol.
2011;12(1):5–9.
49. Boyapati RK, Rossi AG, Satsangi J, Ho GT.Gut mucosal DAMPs in IBD: from mechanisms
to therapeutic implications. Mucosal Immunol. 2016;9(3):567–82.
50. Wu F, Chakravarti S. Differential expression of inammatory and brogenic genes and
their regulation by NF-kappaB inhibition in a mouse model of chronic colitis. J Immunol.
2007;179(10):6988–7000.
51. Li Y, Jiang D, Liang J, Meltzer EB, Gray A, Miura R, Wogensen L, Yamaguchi Y, Noble
PW.Severe lung brosis requires an invasive broblast phenotype regulated by hyaluronan
and CD44. J Exp Med. 2011;208(7):1459–71.
52. Soroosh A, Albeiroti S, West GA, Willard B, Fiocchi C, de la Motte CA.Crohn’s disease
broblasts overproduce the novel protein KIAA1199 to create proinammatory hyaluronan
fragments. Cell Mol Gastroenterol Hepatol. 2016;2(3):358–68. e354.
53. Welter-Stahl L, da Silva CM, Schachter J, Persechini PM, Souza HS, Ojcius DM, Coutinho-Silva
R.Expression of purinergic receptors and modulation of P2X7 function by the inammatory
cytokine IFNgamma in human epithelial cells. Biochim Biophys Acta. 2009;1788(5):1176–87.
54. Souza CO, Santoro GF, Figliuolo VR, Nanini HF, de Souza HS, Castelo-Branco MT, Abalo
AA, Paiva MM, Coutinho CM, Coutinho-Silva R. Extracellular ATP induces cell death in
human intestinal epithelial cells. Biochim Biophys Acta. 2012;1820(12):1867–78.
55. Chen L, Brosnan CF.Regulation of immune response by P2X7 receptor. Crit Rev Immunol.
2006;26(6):499–513.
C. Bernardazzi et al.

8 Environmental Factors andTheir Inuence onIntestinal Fibrosis
56. Pelegrin P, Surprenant A. Pannexin-1 mediates large pore formation and interleukin-1beta
release by the ATP-gated P2X7 receptor. EMBO J. 2006;25(21):5071–82.
57. Neves AR, Castelo-Branco MT, Figliuolo VR, Bernardazzi C, Buongusto F, Yoshimoto A,
Nanini HF, Coutinho CM, Carneiro AJ, Coutinho-Silva R, de Souza HS.Overexpression of
ATP-activated P2X7 receptors in the intestinal mucosa is implicated in the pathogenesis of
Crohn’s disease. Inamm Bowel Dis. 2014;20(3):444–57.
58. Marques CC, Castelo-Branco MT, Pacheco RG, Buongusto F, do Rosario A Jr, Schanaider
A, Coutinho-Silva R, de Souza HS.Prophylactic systemic P2X7 receptor blockade prevents
experimental colitis. Biochim Biophys Acta. 2014;1842(1):65–78.
59. Di Sabatino A, Jackson CL, Pickard KM, Buckley M, Rovedatti L, Leakey NA, Picariello L,
Cazzola P, Monteleone G, Tonelli F, Corazza GR, MacDonald TT, Pender SL.Transforming
growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn’s
disease strictures. Gut. 2009;58(6):777–89.
60. Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT.Blocking
Smad7 restores TGF-beta1 signaling in chronic inammatory bowel disease. J Clin Invest.
2001;108(4):601–9.
61. Stevens EA, Mezrich JD, Bradeld CA.The aryl hydrocarbon receptor: a perspective on
potential roles in the immune system. Immunology. 2009;127(3):299–311.
62. Zhu C, Xie Q, Zhao B. The role of AhR in autoimmune regulation and its potential as a
therapeutic target against CD4 T cell mediated inammatory disorder. Int J Mol Sci.
2014;15(6):10116–35.
63. Busbee PB, Rouse M, Nagarkatti M, Nagarkatti PS.Use of natural AhR ligands as potential
therapeutic modalities against inammatory disorders. Nutr Rev. 2013;71(6):353–69.
64. Suwara MI, Green NJ, Borthwick LA, Mann J, Mayer-Barber KD, Barron L, Corris PA, Farrow
SN, Wynn TA, Fisher AJ, Mann DA.IL-1alpha released from damaged epithelial cells is sufcient and essential to trigger inammatory responses in human lung broblasts. Mucosal
Immunol. 2014;7(3):684–93.
65. Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL.Identication of a key path-
way required for the sterile inammatory response triggered by dying cells. Nat Med.
2007;13(7):851–6.
66. Elkon KB.IL-1alpha responds to necrotic cell death. Nat Med. 2007;13(7):778–80.
67. Bersudsky M, Luski L, Fishman D, White RM, Ziv-Sokolovskaya N, Dotan S, Rider P,
Kaplanov I, Aychek T, Dinarello CA, Apte RN, Voronov E. Non-redundant properties of
IL-1alpha and IL-1beta during acute colon inammation in mice. Gut. 2014;63(4):598–609.
68. Scarpa M, Kessler S, Sadler T, West G, Homer C, McDonald C, de la Motte C, Fiocchi C,
Stylianou E. The epithelial danger signal IL-1alpha is a potent activator of broblasts and
reactivator of intestinal inammation. Am J Pathol. 2015;185(6):1624–37.
69. Scarpa M, Stylianou E. Epigenetics: concepts and relevance to IBD pathogenesis. Inamm
Bowel Dis. 2012;18(10):1982–96.
70. Koukos G, Polytarchou C, Kaplan JL, Oikonomopoulos A, Ziring D, Hommes DW, Wahed
R, Kokkotou E, Pothoulakis C, Winter HS, Iliopoulos D.A microRNA signature in pediatric
ulcerative colitis: deregulation of the miR-4284/CXCL5 pathway in the intestinal epithelium.
Inamm Bowel Dis. 2015;21(5):996–1005.
71. Barnett M, Bermingham E, McNabb W, Bassett S, Armstrong K, Rounce J, Roy N.Investigating
micronutrients and epigenetic mechanisms in relation to inammatory bowel disease. Mutat
Res. 2010;690(1-2):71–80.
72. Cooke J, Zhang H, Greger L, Silva AL, Massey D, Dawson C, Metz A, Ibrahim A, Parkes
M. Mucosal genome-wide methylation changes in inammatory bowel disease. Inamm
Bowel Dis. 2012;18(11):2128–37.
73. Nimmo ER, Prendergast JG, Aldhous MC, Kennedy NA, Henderson P, Drummond HE,
Ramsahoye BH, Wilson DC, Semple CA, Satsangi J. Genome-wide methylation proling
in Crohn’s disease identies altered epigenetic regulation of key host defense mechanisms
including the Th17 pathway. Inamm Bowel Dis. 2012;18(5):889–99.
125

126
74. Sadler T, Scarpa M, Rieder F, West G, Stylianou E.Cytokine-induced chromatin modications
of the type I collagen alpha 2 gene during intestinal endothelial-to-mesenchymal transition.
Inamm Bowel Dis. 2013;19(7):1354–64.
75. Sadler T, Bhasin JM, Xu Y, Barnholz-Sloan J, Chen Y, Ting AH, Stylianou E.Genome-wide
analysis of DNA methylation and gene expression denes molecular characteristics of Crohn’s
disease-associated brosis. Clin Epigenetics. 2016;8:30.
76. Pekow JR, Kwon JH. MicroRNAs in inammatory bowel disease. Inamm Bowel Dis.
2012;18(1):187–93.
77. Zhao Y, Ma T, Chen W, Chen Y, Li M, Ren L, Chen J, Cao R, Feng Y, Zhang H, Shi
R.MicroRNA-124 promotes intestinal inammation by targeting aryl hydrocarbon receptor in
Crohn’s disease. J Crohns Colitis. 2016;10(6):703–12.
78. Rubio-Tapia A, Herman ML, Ludvigsson JF, Kelly DG, Mangan TF, Wu TT, Murray JA.Severe
spruelike enteropathy associated with olmesartan. Mayo Clin Proc. 2012;87(8):732–8.
79. Ianiro G, Bibbo S, Montalto M, Ricci R, Gasbarrini A, Cammarota G.Systematic review: sprue-
like enteropathy associated with olmesartan. Aliment Pharmacol Ther. 2014;40(1):16–23.
80. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE.Scleromyxoedema-like
cutaneous diseases in renal-dialysis patients. Lancet. 2000;356(9234):1000–1.
81. Cowper SE, Bucala R.Nephrogenic brosing dermopathy: suspect identied, motive unclear.
Am J Dermatopathol. 2003;25(4):358.
82. Ting WW, Stone MS, Madison KC, Kurtz K.Nephrogenic brosing dermopathy with systemic
involvement. Arch Dermatol. 2003;139(7):903–6.
83. Grobner T.Gadolinium—a specic trigger for the development of nephrogenic brosing der-
mopathy and nephrogenic systemic brosis? Nephrol Dial Transplant. 2006;21(4):1104–8.
84. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS.Nephrogenic
systemic brosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17(9):2359–62.
85. Swaminathan S, Horn TD, Pellowski D, Abul-Ezz S, Bornhorst JA, Viswamitra S, Shah
SV. Nephrogenic systemic brosis, gadolinium, and iron mobilization. N Engl J Med.
2007;357(7):720–2.
86. Swaminathan S, Bose C, Shah SV, Hall KA, Hiatt KM.Gadolinium contrast agent-induced
CD163+ ferroportin+ osteogenic cells in nephrogenic systemic brosis. Am J Pathol.
2013;183(3):796–807.
87. Swaminathan S, High WA, Ranville J, Horn TD, Hiatt K, Thomas M, Brown HH, Shah
SV.Cardiac and vascular metal deposition with high mortality in nephrogenic systemic brosis. Kidney Int. 2008;73(12):1413–8.
88. Halliwell B.The wanderings of a free radical. Free Radic Biol Med. 2009;46(5):531–42.
89. Stubbleeld MD.Radiation brosis syndrome: neuromuscular and musculoskeletal complica-
tions in cancer survivors. PM R. 2011;3(11):1041–54.
90. Deas SD, Huprikar N, Skabelund A.Radiation exposure and lung disease in today’s nuclear
world. Curr Opin Pulm Med. 2017;23(2):167–72.
91. Harb AH, Abou Fadel C, Sharara AI. Radiation enteritis. Curr Gastroenterol Rep.
2014;16(5):383.
92. Spitz DR, Hauer-Jensen M.Ionizing radiation-induced responses: where free radical chemis-
try meets redox biology and medicine. Antioxid Redox Signal. 2014;20(9):1407–9.
C. Bernardazzi et al.

Chapter 9
Animal Models andSources ofMesenchymal
Cells inIntestinal Fibrosis
DominikBettenworth
Abstract Intestinal brosis is a common complication in patients with Crohn’s
disease (CD) that often results in an impaired quality of life of affected patients. In
the absence of specic anti-brotic medical therapy, patients with stricturing CD
often have to undergo invasive endoscopic treatment approaches or surgical intervention. Beside the lack of medical treatment options for stricturing CD, the diagnostic work-up is hampered by the limited accuracy of methods for detection,
characterization and grading of intestinal brosis. Therefore, functional studies as
well as studies evaluating novel diagnostic and therapeutic approaches for stricturing CD are urgently needed and require appropriate animal models as a prerequisite.
Over recent years, several animal models for intestinal brosis have been established that allow for evaluation of experimental brosis at different stages and in the
context of different pro-brotic triggers. In the following chapter, a variety of animals models will be presented, specic advantages and disadvantages will be
emphasized and the overall relevance and applicability of these models to study
human brostenotic IBD will be discussed.
In the second part of the chapter, different sources of mesenchymal cells, one of
the key executor of intestinal brogenesis, will be discussed. In addition to well
known mechanism such as proliferation and migration of broblasts, novel aspects
such as cellular transdifferentiation including epithelial- and endothelial to mesenchymal transition will be described. Finally, novel techniques to trafc cellular fate
will be displayed.
Keywords Animal model · Intestinal inammation · Trinitrobenzene sulfonic acid
· Dextran sodium sulfate · T cell transfer · Senescence accelerated mice P1/Yit
mouse · Salmonella typhimurium · Radiation · Postoperative brosis · Heterotopic
intestinal transplant model · Mesenchymal cells · Fibroblast · Myobroblasts ·
Epithelial to mesenchymal transition · Endothelial to mesenchymal transition ·
Bone-marrow stem cell · Stellate cells · Pericyte · Fibrocyte
D. Bettenworth
Department of Medicine B, Gastroenterology and Hepatology,
University of Muenster, Muenster, Germany
e-mail: dominik.bettenworth@ukmuenster.de
F. Rieder (ed.), Fibrostenotic Inammatory Bowel Disease,
https://doi.org/10.1007/978-3-319-90578-5_9
127© Springer International Publishing AG, part of Springer Nature 2018

128
D. Bettenworth
9.1 Animal Models ofIntestinal Fibrosis
Animal models may never completely display the complex pathophysiology of
human disease and are inevitably associated with methodological limitations.
However, they represent one of the best available approaches to emerge the pathophysiological understanding as well as to test novel diagnostic and therapeutic
approaches. Furthermore, preclinical data gained from animal models can serve as
a valuable and cost-saving rationale for subsequent studies in human patients.
Animal models for colitis have been introduced and studied for several decades,
however, these models have been predominantly applied to evaluate the involvement of the immune system, the microbiota and inammatory alterations in the
context of inammatory bowel disease (IBD) [1–3]. While not every colitis model
is per se appropriate to equally study intestinal brosis, there is a growing body of
evidence demonstrating that several of the available colitis models qualify as models of intestinal brosis as well [4, 5]. In the following charpter, available brosis
models will be categorized according to the induction of brosis.
Spontaneous models of intestinal brosis are particularly promising since they
do not depend on exogenous stimulation. The senescence accelerated mice (SAM)
P1/Yit mouse starts to develop a spontaneous enteric inammation in the ileum
within 10weeks after birth and reveals a 100% penetrance of brosis by 30weeks
after birth [6]. Beside the ileal disease location, which is the most frequent location
in human CD patients, SAMP1/Yit mice depict further CD-like alterations such as
a transmural and segmental injury accompanied by perianal lesions including stula
development as well as granulomas in the mucosa and submucosa [6, 7]. Microbial
factors are not crucial for this model as SAMP1/Yit mice do not develop inammation under pathogen-free conditions. Functional studies have revealed that the
inammation in the early phase of this model appears to be mediated by CD4
leading to a Th-1-like cytokine prole [8] while the chronic phase is characterized
by Th2 responses [9]. A major drawback of this model is the low breeding rate and
the limited commercial availability.
Targeted manipulation of genes is a widely used approach to study the impact of
inammatory pathways related to IBD.With regard to intestinal brosis, several
genetically induced models are available. The targeted disruption of the IL-10 gene
in mice leads to a spontaneous chronic enterocolitis [10, 11]. While a rather mild
colonic inammation is observed in IL-10-decient mice under pathogen-free conditions, animals under conventional housing conditions show mucosal inammation
in the upper and lower intestinal tract as well as systemic signs of inammation such
+
as anemia [10]. Colitis manifestation is dependent on CD4
T cells and mediated by
IFN-γ since anti-INF-γ antibody administration was elegantly shown to ameliorate
the disease course in IL-10-decient colitic mice [12]. Colitis induction in this
model can be accelerated and aggravated by oral administration of cyclooxygenase
isoform-selective inhibitors such as piroxicam which act through a blockade of
endogenous prostaglandin production [11]. Importantly, the molecular disease pattern of this model changes over time from a Th1-driven phenotype in early stages
+
cells

9 Animal Models andSources ofMesenchymal Cells inIntestinal Fibrosis
129
towards a predominant Th2-driven phenotype with increased IL-4 and IL-13 synthesis in later disease stages [13]. Of note, recent work has pointed out the relevance
of IL-13in the pathogenesis of intestinal brosis [14, 15]. This fact together with
the observation that increased ECM levels were found in the intestine of IL-10decient mice, emphasize the applicability of this model to study intestinal brogenesis [16].
TGF-β1 is a core mediator for initiation and perpetuation of brogenesis in general and has also been identied as a key driver for intestinal brogenesis in IBD
patients [17, 18]. Accordingly, genetically-engineered mice owing a TGF-β overexpression represent a promising research tool to study brogenesis. Vallance etal.
demonstrated that mice treated by TGF-β1 gene transfer via rectal enema delivery
will rst develop inammatory alterations of the intestine within 2 weeks [19].
Subsequently, these animals present with marked brotic alterations including massive collagen deposition, myobroblast inltration and colonic wall thickening and
obstruction in up to 50% of treated mice. Fibrotic alterations in this model appear
focally along the colon and mortality rates of this model are below 10% [19].
The cytokine monocyte chemoattractant protein 1 (MCP-1) is well known to
play a crucial role in mediating brotic alterations in different organs such as the
lung, the kidney and the liver [20–22]. MCP-1 is capable to attract different cell
types including monocytes, T and NK cells. Furthermore, MCP-1 expressionw as
found to be enhanced within the submucosa and muscularis propria of CD patients
as compared to healthy controls [23]. Intramural gene transfer via an adenovector
endoding for murine MCP-1 resulted in transmural inammation and induction of
brosis reected by an increased collagen accumulation from day 3–21 post gene
transfer [24]. Furthermore, probrotic markers such as TGF-β1 and tissue inhibitor
of matrix metalloproteinase 1 (TIMP-1) were found to be increased at day 7 post
−/−
vector transfer. In contrast, T and B cell-decient RAG2
mice did not respond
with collagen deposition upon gene transfer pointing at a crucial role for lymphocytes in this model [24].
Chemically-induced models of brosis depend on the external administration of
variable agents that induce an inammatory response of the intestine through intestinal epithelial injury or direct activation of immune cells. As a consequence of a
epithelial barrier defect, microbiota can penetrate the colonic wall, interact with
local immune cells of the lamina propria and thus initiate or maintain inammation
which in turn may futher fuel brogenesis.
The trinitrobenzene sulfonic (TNBS) acid-induced intestinal brosis model is
one of the most commonly applied chemically-induced models [25]. Rectally
administered TNBS (usually diluted in ethanol to induce epithelial damage) acts as
a hapten causing a T cell dependent transmural inammation [26, 27]. Repetitive
rectal TNBS application of increasing doses results in a chronic colitis accompanied
by intestinal brosis that may become evident by luminal stenosis and bowel dilatation [28]. In this chronic stage, the disease pattern is characterized by elevated levels
of Th2 cytokines and TGF-β1. More specically, TGF-β1 expression was shown to
be at least partially dependent on IL-13 [4]. In addition, application of an antisense
oligonucleotide directed against the pro-inammatory transcription factor NF-κB

130
D. Bettenworth
was shown to ameliorate TNBS-induced brogenesis indicating that this modell is
NF-κB dependent [29]. However, this effect may also be mediated by the antiinammatory action of a therapeutic NF-κB blockade. Finally, mast cells and neuropeptides such as substance P are linked to brogenesis in the TNBS-induced
colitis model since a mast cell blockade and neuropeptide antagonism were shown
to result in a reducted brotic alterations of TNBS-challenged mice [30, 31]. A
major limitation of the TNBS model is that brotic alterations are restricted to areas
of TNBS installation and depend on the hapten dosing. While low doses may be
insufcient to induce an appropriate degree of inammation, higher doses may
cause high mortality rates. In addition, appropriately susceptible mouse strains are
required to successful apply the TNBS-induced model. Regrettably, the commonly
used C57Bl/6 WT mice does not appear to be particular susceptible to TNBSinduced brosis.
Oral administration of dextran sodium sulfate (DSS), a complex polymer of glucose, in the drinking water of mice results in a experimental colitis, mediated by
toxic DSS effects leading to impaired proliferation of epithelial cells, break down of
the epithelial barrier and recruitment of macrophages [25]. In addition, chronic DSS
administration in some mouse strains induces marked brotic alterations with
increased TGF-β and MMP-2/-9 expression [32, 33]. One major advantage of this
chemically-induced brosis model is the easy route of DSS-application as compared to TNBS for example. On the other hand, the degree of intestinal brosis is
modest and brosis will not be found in the ileum. The penetrance rate of brosis
may be increased by extending or repetition of DSS administration [5], however,
due to its toxic nature, the overall transferability of this model to human IBD may
be limited.
Several years ago, it was reported that peroxynitrite, an oxidant and nitrating
agent, rectally administered into the colons of rats lead to narrowing of the colonic
lumen and signs of stenosis at day 21 [34]. Furthermore, histopathological analyses
showed transmural colitis and thickening of the muscularis mucosae and muscularis
propria reecting manifest brosis.
The vast majority of animal models for IBD were intended to study the role of
the intestinal immune responses during inammation. Later on, some of these models such as the DSS-induced colitis model were extended to assess the chronic phase
of intestinal inammation. Additionally, this extension allows for investigation of
intestinal brosis. The T cell transfer-induced colitis represents the most commonly
used immune-mediated model for intestinal brosis. In this model, the intravenous
high
injection of naïve CD45RB
CD4+ T cells into immunodecient SCID mice results
in a strong transmural colitis [35, 36]. In addition to an inammatory cell inltrate
containing neutrophils, lymphocytes and macrophages, a narrowing of the intestinal
lumen can be observed due to the accumulation of stromal cells reecting brotic
alterations of the T cell transfer model [37]. This observation has been conrmed by
histopathological studies, however, the overall brosis development in this model
appears to be rather less frequent.
There is a growing body of evidence, that microbioata is a key driver of intestinal
brogenesis in human IBD patients as well as in experimental models of brosis [38].

9 Animal Models andSources ofMesenchymal Cells inIntestinal Fibrosis
131
Accordingly, several experimental approaches have been used to establish bacteria-
induced models of brosis.
Peptidoglycan-polysaccaride (PG-PS), a bacterial cell wall polymer induces a
transmural colitis when injected into the colonic wall of rats [39]. After a chronic
inammatory phase of 3weeks, a brotic thickening of the intestinal wall with associated adhesions can be observed. Furthermore, increased tissue levels of TGF-β1
and IGF-I were found [40]. While this model allows reproducible investigation of
different stages of brosis, it is technically challenging and is only partially transferred to mice by now [41].
Similarly to the latter model, a fecal suspension of various aerobic (Lactobacillus
ssp., Enterobacter aerogenes, Klebsiella pneumoniae and Streptococcus viridans)
and anerobic bacterial strains (Clostridium ramnosum, Bacteroides fragilis and
Bacteroides uniformis) was found to induce brosis when injected into the colonic
wall of rats. Treated animals showed signs of chronic inammation and brosis
with stricture development. Additionally, TGF-β1 and collagen synthesis were signicantly enhanced [42]. Subsequent work demonstrated an increased production
of TGF-β1 stimulated Smad2/3 phosphorylation and enhanced ALK5, TIMP-1, and
α2 type 1 collagen gene expression [43]. Slight modications of this models indi-
cated that inoculation with single anaerobic strains such as Clostridium ramosum or
Bacteroides fragilis (but not with aerobic) strains was able to induce collagen deposition. These observations emphasize the impact of commensal gut microbiota on
TGF-β1 and collagen production and the impact on intestinal brogenesis in
general.
In addition, oral administration of live bacteria such as Salmonella enterica
serovar Typhimurium can be used to establish intestinal brosis in mice. In this
model, 24hours after antibiotic pre-treatment with streptomycin, the ingestion of
Salmonella typhimurium results in colitis development, which can be accompanied
by marked brotic alterations of the cecum and colon that further aggravated over
the following 3weeks [44]. Functionally, it was shown that the Salmonella virulence factors Salmonella pathogenicity islands (SPI)-1 and SPI-2 are essentiell for
brosis induction in this model. Furthermore, enhanced production of TGF-β1, connective tissue growth factor (CTGF) and IGF-I was documented accompanied by
increased broblast accumulation [44]. Targeted elimination of the inammatory
stimulus by antibiotic treatment may be used to assess the specic impact of inammation on brogenesis at different time points. This model is easy to perform and
shows good reproducibility in various mouse strains as well as in geneticallymodied mice. However, the relevance to human brostenotic IBD may be limited
by the fact that Salmonella infection does not contribute to stricture development in
human CD patients.
A specic subset of E. coli with acquired virulence factors was identied being
capable to adhere and invade the intestinal epithelium which in turn leads to an
inammatory response in human CD patients. 21days after oral gavage of so-called
adherent invasive E.coli (AIEC) to CD1 mice pretreated with streptomycin, a transmural inammation of the caecum with edema and crypt hyperplasia was observed.
Similarly treated C57Bl/6 mice additionally developed submucosal ulcerations as

132
D. Bettenworth
well as thickened mucosa indicative of crypt hyperplasia. Macroscopic assessment
of ileal specimen from both strains revealed epithelial destruction and crypt ulcerations. Colonic and ileal inammation in CD1 and C57Bl/6 mice was characterized
by a signicant increase in TNF-α, INF-γ and IL-17. Furthermore, immunohistological analyses using Masson’s trichrome and picrosirius staining visualized progressive ECM deposition being more pronounced in caecal than in colonic samples
from AIEC-treated mice. In accordance with these histomorphological changes,
increased expression levels of TGF-β, CTGT and IGF1 were detected [45].
Based on the phenomenon that colonic exposure to therapeutic radiation can
result in relevant intestinal brosis, radiation-induced models of intestinal brosis
were invented. Radiation-induced thickening of the bowel wall is characterized by
an enlarged submucosa, increased proliferation rates of broblasts and smooth muscle cells as well as enhanced accumulation of collagen and other ECM elements
[46]. Core features of radiation-induced intestinal brosis are vascular sclerosis
with endothelial dysfunction and chronic ulcers. Of note, the degree of brosis can
increase up to 26weeks following radiation and is mainly inuenced by the applied
radiation dose, fraction size as well as the time between several radiation procedures
[47, 48]. Two different experimental settings for this approach have been proposed.
In the rst model, a small bowel segment is resected, exernally irradiated and the
re-implanted into the animal [49, 50]. In an alternative approach, a 4-cm segment of
the distal ileum is transferred into the scrotum after a orchiectomy has been performed; since this location is easy accessable for radiation [51]. The radiation
results in an acute inammatory response with colitis und ulcer development and
induction of brotic alterations in the stromal compartment. This multicellularmediated response is partially dependent on inammation with microvascular
insults being an early stimulus that is accompanied by subsequent hypoxia [52].
Subsequently, common brotic alterations including probrotic cytokine production such as TGF-β1 and CTGF, broblast proliferation and increased collagen production are observed [53]. In addition, activation of mast cells, Rho-associated
kinase (ROCK) signaling pathways, endothelial dysfunction and activation of
capsaicin- sensitive nerves represent additional, more specic response of the irradiated bowel [54].
It is a well-known clinical observation that up to 40% of CD patients being
treated by intestinal resection will suffer from a symptomatic recurrence within the
rst 3years after surgery, that may further culminate in postoperative brosis development and anastomotic stenosis [55]. Recently, an animal model for postoperative
brosis has been described. Rigby etal. performed a ileocecal resection in IL-10decient mice and WT mice. In contrast to the WT control group, IL-10-decient
mice developed inammation-driven brosis at the proximal site of the anastomosis
[56]. Importantly, germ-free housed IL-10-decient mice did not develop brosis
after ileocecal resection indicating that the innate immunity is part of this model
[57]. Furthermore, in a model of colonic resection, an enhanced myobroblast
growth and differentiation at the anastomosis was observed [58]. In addition to restenosis of the anastomosis, occurrence of postsurgical adhesions reect another

9 Animal Models andSources ofMesenchymal Cells inIntestinal Fibrosis
aspect of postoperative brosis. Serosal abrasion of the murine cecum can be easily
performed and adhesions could be veried within 6days [59]. Interestingly, executors of the adaptive immune system such as CD4+ Th1 are involved in adhesion
development by regulating chemokine production and leukocyte trafcking. In
addition, a protective role of microbial polysaccharides and IL-10 regarding adhesion formation was observed [60, 61].
Recently, an experimental model of tracheal transplantation to study bronchiolitis obliterans was transferred into a heterotopic intestinal transplant model to elu-
cidate intestinal brosis. To this aim, 3 cm small bowel resections of rats were
transplanted into the neck of recipient rats [62]. The intestinal transplants were
shown to be viable for 3weeks. Beginning from day 2 after transplantation, loss of
crypt architecture and lymphocyte inltration was observed and resulted in brotic
narrowing of the intestinal lumen by day 21. Additionally, collagen expression,
TGF-β synthesis and IL-13 production were signicantly increased over time [62].
While this model is considered to be rather articial, it was shown to be appropriate
to evaluate anti-brotic potential drug candidates [63, 64].
133
9.2 Relevance andApplicability ofExperimental Models
ofFibrosis toStudy Human Fibrostenotic Inammatory
Bowel Disease
Clinical trials in brostenotic IBD patients are challenging due to several reasons.
By now, no ideal target for intestinal brosis has been identied and the optimal
timing of a anti-brotic treatment is unknown. In addition, appropriate biomarkers
to facilitate an early risk stratication are not available and the ideal route of administration for anti-brotic drug candidates is unknown [65]. Therefore, the use of
animal models is inevitable to further elucidate intestinal brogenesis and to evaluate novel diagsnotic and therapeutic approaches in order to improve quality of life
of IBD patients with brostenotic complications.
Depending on the specic study hypothesis, one has to decide which model to
apply. Of note, most of the above mentioned models have been established to study
different aspects of the immune systems in the context of experimental colitis.
Giving the experimental set-up, it is obvious that these models do not imply all
pathogenic components of human patients suffering from intestinal brosis. For
example, as chemically-induced models of brosis largely depend on an impaired
epithelial barrier function upon administration of toxic substances, these models
may not reect the physiological insult that leads to intestinal brosis but may be
particulary suitable to study the role of the innate immune system during brosis
development. Furthermore, with regard to the commonly used TNBS model, variability of successful colitis induction depending on the optimal amount of TNBS
may be challenging. Genetically-induced models of brosis usually feature single
gene modication that do not reect the underlying polygenetic alterations in IBD
Соседние файлы в папке Библиотека им академика М.И. Перельмана
